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Hematopoietic stem cell transplantation
Colitis
Exome sequencingPediatric-onset inﬂammatory bowel disease (IBD) is known to be associated with severe disease, poor
response to therapy, and increased morbidity and mortality. We conducted exome sequencing of two
brothers from a non-consanguineous relationship who presented before the age of one with severe
infantile-onset IBD, failure to thrive, skin rash, and perirectal abscesses refractory to medical management.
We examined the variants discovered in all known IBD-associated and primary immunodeﬁciency genes in
both siblings. The siblings were identiﬁed to harbor compound heterozygous mutations in IL10RA
(c.784CNT, p.Arg262Cys; c.349CNT, p.Arg117Cys). Upon molecular diagnosis, the proband underwent suc-
cessful hematopoietic stem cell transplantation and demonstrated marked clinical improvement of all IBD-
associated clinical symptoms. Exome sequencing can be an effective tool to aid in the molecular diagnosis
of pediatric-onset IBD. We provide additional evidence of the safety and beneﬁt of HSCT for patients with
IBD due to mutations in the IL10RA gene.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Inﬂammatory bowel disease (IBD) is a chronic inﬂammatory condi-
tion of the intestinal tract composed of two somewhat clinically distinct






ghts reserved.to affect approximately 2.5 million people. IBD is a result of an inap-
propriate and uncontrolled inﬂammatory response to commensal
intestinal microbes [1]. Despite a well-recognized genetic compo-
nent, IBD is a complex multifactorial disorder characterized by a
genetic predisposition, but in general, development of disease is
still dependent upon the interactions of these genetic variations
with the gut and intestinal ﬂora, and environmental factors [2].
To date, genome wide association studies (GWAS) have identiﬁed
at least 163 loci encompassing more than 300 genes that are associated
with IBD [3]. Genes in at least seven distinct, but interrelated, pathways
have been found to be associated with IBD through GWAS studies,
including those involved in the epithelial barrier and junctions, innate
immune sensors, g-protein coupled receptors, IL-10 signaling, the
Th17 pathway, T-cell negative regulators, and B-cell function [1,2,4].
Within these pathwaysmultiple genes involved in cellular responses in-
cluding autophagy, ER stress, intracellular logistics, cell migration, apo-
ptosis/necroptosis, carbohydrate metabolism, and oxidative stress have
been implicated. Furthermore, genes more directly involved in
immune-mediated intestinal homeostasis including the epithelial barri-
er, restitution, solute transport, Paneth cells, innate mucosal defense,
443D.L. Dinwiddie et al. / Genomics 102 (2013) 442–447immune cell recruitment, antigen presentation, IL-13/Th17, T-cell regu-
lation, B-cell regulation, and immune tolerance also play a critical func-
tion in IBD [1,2,4]. Despite the success of GWAS at discovering pathways
involved in the pathophysiology of IBD, the studies have largely failed to
identify actual causal variants.
However, multiple monogenic causes of IBD with causal variants
of high effect have been recently identiﬁed. Mutations in the gene
encoding the X-linked inhibitor of apoptosis (XIAP) [5] have linked to
early-onset severe colitis and the interleukin 10 (IL10) [6] and its asso-
ciated receptor alpha and beta subunits (IL10RA and IL10RB) [7] have
been shown to cause very-early-onset IBD (VEO-IBD). The Paris classiﬁ-
cation deﬁnes early-onset IBD (EO-IBD) as diagnosis before the 18th
birthday, VEO-IBD as diagnosis before the age of six years old, and
infantile-onset IBD as diagnosis before the 1st birthday [8]. It is like-
ly that genetic factors contribute more to the etiology of IBD in cases
where multiple family members are affected, in infantile-onset and
VEO-IBD, and in cases demonstrating extreme clinical phenotypes.
To that end, we enrolled two siblings with onset of IBD prior to
one year of age, which was refractory to medical management
into the Children's Mercy Undiagnosed Disease Research Program
to undergo exome sequencing.
2. Case presentations
The proband, CMH000166, is an 8 year old male who presented
at 6 months of age with perirectal abscess and failure to thrive. Within
the ﬁrst year of life he developed anemia, diarrhea, failure to thrive and
skin rash (Table 1, Supplement Fig. 1). Endoscopic evaluation revealed
features consistent with Crohn's disease affecting his upper GI tract and
colon. There were multiple perianal cutaneous abscesses and colon
biopsy revealed crypt destruction, crypt distortion and occasional
crypt abscessed with patchy basal plasmacytosis (Fig. 1). Addition-
ally, skin biopsy revealed neutrophilic dermatosis. Medical treat-
ment with azathioprine, inﬂiximab (10 mg/kg), adalimumab and,
ﬁnally, tacrolimus failed to adequately control his disease, resulting
in corticosteroid dependence. Enteral nutrition was attempted but
failed to restore normal growth velocity. Refractory, severe disease
resulted in a colectomy at age 3, ileal resection at age 5, and over 20hos-
pitalizations. CMH000165 is the 16 month old younger brother of the
proband who presented at two months of age with oral lesions and de-
creased oral food intake, and was seen again at four months of age with
oral lesions, anemia, failure to thrive and perianal skin rash (Table 1,
Supplement Fig. 2). Biopsies obtained at Esophagogastroduodenoscopy
and ﬂexible sigmoidoscopy revealed esophagitis and colitis with the
presence of granulomas. He is corticosteroid dependent, having failed
tacrolimus and inﬂiximab. Currently he is treatedwith 1 mg/kg of pred-
nisone, elemental diet, night time parenteral nutrition, azathioprine
and adalimumab, yet is still affected with persistent inﬂammation
and perianal disease and has a weight z-score of −4. Both siblings
had a signiﬁcantmedical history of increased susceptibility to infections
consistent with a primary immunodeﬁciency (PID). CMH000166 hadTable 1
Clinical summary of patients.
CMH000166 CMH000165
Age 8 years 16 months
Gender Male Male
Onset of symptoms 6 months 2 months
Perianal disease + +
Extent of disease Upper disease proximal













Neutrophilic dermatosisthree separate methicillin-sensitive Staphylococcus aureus (MSSA)
infections and multiple upper respiratory and sinus infections by
the age of 5 years. The younger sibling, CMH000165, had three infec-
tions of Enterococcus faecalis and multiple severe rotavirus, rhinovirus,
parainﬂuenza virus and respiratory syncytial virus infections. Immuno-
logical evaluation of CMH000166 revealed mildly elevated IgA at
262 mg/dl2 (normal 13.9–105 mg/dl2), but normal IgG, IgM, C3
and C4 levels. In the younger sibling, CMH000165, slightly elevated
IgG, IgM, IgA and IgE levels were noted.
3. Results
Given the severe and early onset of disease in a sibling pair, a mono-
genic cause of either autosomal recessive or X-linked inheritance was
suspected. Consequently, both parents and the siblings were enrolled
in a research protocol to have their exomes sequenced by the Center
for Pediatric Genomic Medicine (CPGM) at Children's Mercy Hospital
[9–11]. Brieﬂy, DNA was isolated from peripheral blood of the affected
siblings and their non-consanguineous, nonaffectedparents and enriched
for 62.2 million bases representing the coding regions of the genome
(Illumina v1) and sequenced by Illumina next-generation sequencing.
Alignment, variant detection, and characterization were performed as
previously described [10]. The exomes of CMH000165 and CMH000166
received 10.7 and 11.9 gigabases of sequencewhich resulted inmean tar-
get coverages of 83.4× and 92.2×, respectively (Supplement Table 1).
Less than 3% of the targeted exome received 0× coverage, and 90%
received 20× coverage (Supplement Table 1). A total of 116,020 variants
were detected in CMH000165 and 117,583 variants were detected in
CMH000166 (Supplement Table 2). Variant characterization by RUNES
resulted in 24 category 1 variants in CMH000165 and 27 category 1 var-
iants in CMH000166 (Supplement Table 2). Analysis of category 1 vari-
ants revealed that both siblings were compound heterozygous for two
missense mutations in the IL10RA gene. Mutation 1 was inherited from
the mother (c.784CNT, p.Arg262Cys, Supplement Fig. 3) [12] and muta-
tion 2was inherited from the father (c.349CNT, p.Arg117Cys, Supplement
Fig. 4) [13]. The siblings were found to share 11 category 2 variants with
an allele frequency of less than 1%. However, all of the identiﬁed category
2 variants were heterozygous and not consistent with an autosomal
recessive or X-linked inheritance pattern. Furthermore, none of the cate-
gory 2 variants were in genes associated with disease and thus, were all
deemed likely to be nonpathogenic and unrelated to the clinical pheno-
type (Supplement Table 3).
To further exclude other potential high effect IBD-associated rare
variants we examined the variants discovered in both siblings in 301
genes (Supplement Table 4) associated with IBD through GWAS stud-
ies [3]. In addition, we wanted to investigate potential causes of the
immune-related dysfunction seen in our siblings that might be due
to mutations other than the IL10RAmutations discovered; therefore,
we analyzed variants found in 90 known primary immunodeﬁciency
(PID) genes (Supplement Table 5) [14]. Given the familial inheri-
tance pattern, the severity of IBD in our patients, and the known
low frequency of PIDs in the population we decided to examine only
rare variants in coding or splice sites with an allele frequency of less
than 1%. Consequently, only nonsynonymous, insertion/deletion, and
variants that were predicted to impact splicing and that were found to
be at a frequency of 1% or less in dbSNP v137 [15], the 1000 Genomes
Project [16] or CPGM internal variant database [9,10], were evaluated.
Using these ﬁltering criteria 338 variants in CMH000165 and 377
variants in CMH000166 were analyzed. Surprisingly, only four vari-
ants were found in the IBD-associated genes (Supplement Table 6)
and zero variants were discovered in either sibling in the 90 PID
genes analyzed. Of the four variants discovered in IBD-associated
genes, three were shared by the siblings. Further analysis of the
four genes revealed only two, TXK tyrosine kinase and chemokine
(C–C motif) receptor 6, with demonstrated function in pathways
known to be associated with IBD; however, both variants were
Fig. 1. Clinical ﬁndings of CMH000166. Perianal abscesses (A, B), colon biopsy with crypt destruction (C), crypt abscess and basal plasmacytosis (D).
444 D.L. Dinwiddie et al. / Genomics 102 (2013) 442–447previously seen in patients sequenced at CMHwho did not have clinical
symptoms of IBD and consequently were judged to be nondisease-
causing. Taken together, the presence of twomutations with functional
characterization and previously reported in VEO-IBD patients with the
lack of additional disease-causing mutations in 301 genes associated
with IBD by GWAS and 90 known PID genes the two mutations in
IL10RA were deemed sufﬁcient to be diagnostic. Consequently, conﬁr-
matory clinical capillary sequencing was conducted and the molecular
diagnostic results were returned to the treating physicians.
There is compelling, but limited data, suggesting the clinical utility of
hematopoietic stem cell transplantation (HSCT) to induce remission ofFig. 2. Hematopoietic stem cell traclinical symptoms in patients with IL10R mutations [7,13,17]. At
the time of molecular diagnosis, CMH000166 had a weight Z-score
of −3.91, his height plateau Z-score was −2.48, and his bone den-
sity T-score was −3.1. The patient was on tacrolimus and 2 mg/kg
of prednisone. A magnetic resonance enterography (MRE) revealed
narrowing of the ileum which was going to require bowel resection.
In response to CMH000166's severe clinical condition and previous
reports of treatment by HSCT, his parents decided to proceed with
the procedure. An unrelated 10 out of 10 match was found. Brieﬂy,
the reparatory regimen for transplant consisted of Campath, busul-
fan and ﬂudarabine and graft versus host prophylaxis consisted ofnsplant preparatory regiment.
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prophylaxis with metronidazole and ciproﬂoxacin during and after
transplantation. The patient engrafted on day 21 post-HSCT as indi-
cated by short tandem repeat analysis of peripheral blood (98%
donor cells). He required one platelet transfusion, with an adverse
reaction of rash, hypotension, and angioedema with swelling of the
throat and tongue. His immediate post-transplant course was compli-
cated by severe rotavirus diarrhea and Enterococcus hirae and Klebsiella
pneumoniae bacteremia, necessitating hospital readmission on day 24
post-HSCT. Following intensive treatment to control the infections, the
patient was released from the hospital on day 71 post-transplant. Fur-
ther complications occurred on day 100 post-transplant when the
patient presented with a low grade fever and swelling on the right
side of the neck due to painful lymphadenopathy. Epstein bar virus
(EBV) PCR showed 2500 copies in the plasma. A repeat PCR three days
later showed 17,000 copies of EBV. Ultrasound of the abdomen revealed
enlargement of the spleen and porta-hepatis lymph node enlargement.
A computed tomography (CT) scan of the chest revealed three nodular
opacities with the largest being 4 mm in the left upper lobe. Biopsy of
lymph nodes from the neck conﬁrmed monomorphic clonal B cell
post-transplant lymphoproliferative disorder (PTLD). The patient was
treated with two doses of Rituxan weekly and withdrawal of immuno-
suppressants. His lymphadenopathy subsequently resolved, and EBV
viremia subsided and he was released from the hospital.
Subsequently, to better understand the rare, nonsynonymous vari-
ant burden and impact of mutations in the IL10RA gene, we examined
the number of variants of a frequency of less than 1% in the IL10RA
gene in the CPGM internal variant database [9,10]. Brieﬂy, this database
keeps track of every variant detected at the CPGM, at what frequency
the said variant has been seen and the clinical phenotype of each patient
that the variant was found in. In more than 1300 exomes sequenced at
the CPGM, 19 nonsynonymous variants with a frequency of less than 1%
have been identiﬁed (Supplement Table 7). Of these, 42% are predicted
to be deleterious by SIFT (Sorts Intolerant From Tolerant substitutions)
[18] and 37% as possibly damaging by PolyPhen2 (Polymorphism
Phenotyping 2) [19] (Supplement Table 7). Interestingly, in the CPGM
database the only samples that contain two predicted deleterious
and possibly damaging variants are the siblings reported here and
none of the patients harboring a single, heterozygous damaging variant
exhibited clinical IBD symptoms.
4. Discussion
Deﬁnitive molecular diagnosis of VEO-IBD is especially challenging
due to locus heterogeneity and overlapping signs and symptoms of
monogenic and complex forms of IBD. However, increasing evidence
suggests that rare, highly penetrant genetic variants may exist for
many common diseases [20–22].Whole exome and genome analysis
of familial cases is one method to discover these. Currently, diagno-
sis of affected individuals with VEO-IBD and other rare genetic disor-
ders is lengthy and costly – the “diagnostic odyssey” – and in many
patients a deﬁnitive molecular diagnosis is never achieved despite
extensive clinical investigation. In response to these needs, our hospital
started an undiagnosed childhood disease program two and a half years
ago, and has enrolled over 500 individuals. They received genome,
exome, or targeted panel sequencing and analysis at no cost in addition
to extensive conventional clinical investigation.
Here,we report the clinical utility of exome sequencing to determine
the molecular cause of infantile-onset IBD in siblings, which enabled
personalized therapy. Both mutations found in our patients have previ-
ously been reported independently, p.Arg117Cys in a compound het-
erozygous patient [13] and p.Arg262Cys as a homozygous mutation in
a patient with VEO-IBD [12]; however, this is the ﬁrst report of
these two mutations together causing VEO-IBD. Importantly, in
contrast to most reports to date [6,7,13,23], our siblings are from a
non-consanguineous union and highlight that a monogenic causeof VEO-IBD should not be overlooked when the parents are not
related. Of note, the duration from the time of enrollment in the
undiagnosed disease program to the time of return of molecular
results to the physician was approximately one month demonstrat-
ing the potential speed of diagnosis through exome sequencing. In
addition, we present further evidence that IL10 receptor mutations
should be considered in the differential diagnosis of infantile-onset and
VEO-IBD, particularly in patients with severe phenotypes including
aggressive disease, perianal lesions and dermatosis.
By conducting whole exome sequencing we were able to make
a more deﬁnite diagnosis than a targeted approach might provide
because wewere able to excludemore potential mutations and exclude
other causes of the clinical symptoms.We found only four variants with
a frequency of less than 1% in 301 IBD-associated genes (Supplement
Table 6). Of the four variants discovered in IBD-associated genes, three
were shared by the siblings; however, zero variants were judged to be
disease-causing in their heterozygous state as they were previously
seen in patients sequenced at CMHwho did not have clinical symptoms
of IBD. Furthermore, we were also able to exclude a secondary cause of
immune dysfunction by analyzing 90primary immunodeﬁciency genes.
Our analysis did not reveal a single known or likely disease-causingmu-
tation in any of these genes in either sibling, providing further evidence
to the support the mutations in the IL10RA as the likely cause of the im-
mune dysfunction. However, it should be cautioned that it can be difﬁ-
cult to distinguish primary immune dysfunction as a result of impaired
IL10 signaling from those related to the immunosuppressive treatments
that most of the children with severe IBD are on.
We provide further evidence of the beneﬁt of HSCT for patients with
VEO-IBD due tomutations in the IL10RA gene. CMH000166underwent a
successful HSCT that leads to the clinical remission of his IBD; however,
it was not without complications. Within days of release from the hos-
pital a severe rotavirus infection required readmission to the hospital.
Interestingly, sequencing of the rotavirus infection revealed a wild-
type strain possibly contracted from his younger sibling. Previous stud-
ies have also reported severe viral infections in IL10R patients post-
transplantation [7,13,17], suggesting that this patient population may
be at risk for atypical post-transplant viral infections. In addition,
CHM000166 also developed post-transplant lymphoproliferative disor-
der. Despite the complications of the HSCTmarked clinical improvement
in the child was noted, including increased weight gain, improvement
in energy and endurance, and complete elimination of GI symptoms
and dermatitis seven months post-transplant. A stem cell donor has
been identiﬁed for the younger sibling, CMH000165, and a HSCT is
being scheduled.
A recent study found IL10R polymorphisms to be associated with
very-early-onset ulcerative colitis [24]. In the CPGM's internal exome
database with more than 1300 samples we found 11 variants in the
IL10RA including the two reported here and only 2 variants in the
IL10RB genewith a allele frequency of less than 1%, suggesting that dam-
agingmutations in these two genes are indeed infrequent. Of note, none
of the sampleswithmutations in either gene had IBD-associated clinical
symptoms mentioned and two were found in healthy parents of chil-
dren with an unrelated rare disease.
Deﬁnitive molecular diagnosis has several potential beneﬁts that
we've previously discussed [25]. First, in this family it provided a treat-
ment option that might not otherwise have been considered. HSCT is
arduous and not without risk, but at the time of molecular diagnosis
two separate reports [7,13] suggested in patients with IL10 pathway
mutations that it was an effective and potentially the only long-term
treatment option.With this information, both the family and physicians
were able to weigh the risk-beneﬁts and make an informed clinical
management decision. Second, identifying amolecular cause of amono-
genic disorder allows for genetic counseling about recurrence risks
in the family and their relatives. In this case, the family now knows
that any additional pregnancy has a 25% chance of the child also being
affected. Third, it helps improve variant databases with regard to both
446 D.L. Dinwiddie et al. / Genomics 102 (2013) 442–447pathogenicity of speciﬁc variants and frequency within a population.
This, the second and third reports of patients with VEO-IBD harboring
these speciﬁc mutations add evidence to their pathogenicity.
In summary, the clinical and genetic heterogeneity of VEO-IBDmakes
it a particularly good candidate for exome sequencing; however there is
insufﬁcient data to date on the clinical yield in VEO-IBD. We report at
least in an isolated familial case with infantile-onset IBD that exome
sequencing is indeed beneﬁcial for molecular diagnostic and clinical
management purposes. However, additional studies are needed to
examine the speciﬁcity and sensitivity of genome or exome sequencing
before they are considered a primary diagnostic tool for patients with
VEO-IBD.5. Methods
5.1. Consent
The study was approved by the Institutional Review Board of
Children's Mercy Hospital (CMH). Informed written consent was
obtained from adult subjects and assent was obtained from the
parents of the children.5.2. Targeted exome sequencing
Exome sequencingwas performed at the Center for Pediatric Genomic
Medicine (CPGM) at CMH under a research protocol. Isolated genomic
DNA was prepared for sequencing using the Kapa Biosystems library
preparation kit and 8 cycles of PCR ampliﬁcation. Exome enrichment
was conducted with the Illumina TruSeq Exome v1 kit (62.2 megabases)
following a slightly modiﬁed version of the manufacturer recommended
protocol. The enrichment protocol was modiﬁed to use the Kapa
Biosystems PCR ampliﬁcation kit for the post-enrichment ampliﬁca-
tion step to limit polymerase induced GC-bias [26]. Successful
enrichment was veriﬁed by qPCR of 4 targeted loci and 2 non-
targeted loci of the sequencing library pre- and post-enrichment
prior to sequencing [27]. The enriched library was sequenced on
an Illumina HiSeq 2000 using v3 reagents and 1 × 101 base pair
sequencing reads.5.3. Next generation sequencing analysis
Sequence data was generated with Illumina RTA 1.12.4.2 &
CASAVA-1.8.2, aligned to the human reference NCBI 37 using the
Genomic Short-read Nucleotide Alignment Program (GSNAP) [28] and
variants were detected and genotyped using the Genome Analysis
Toolkit (GATK) [29]. Sequence analysis employed FASTQ ﬁles, the com-
pressed binary version of the Sequence Alignment/Map format (bam, a
representation of nucleotide sequence alignments) and Variant Call
Format (VCF, a format for nucleotide variants). Variantswere character-
ized with the CPGM's Rapid Understanding of Nucleotide variant Effect
Software (RUNES v1.0) [10]. RUNES incorporates data from the Variant
Effect Predictor (VEP) software [30], and produces comparisons to NCBI
dbSNP, knowndiseasemutations from theHumanGeneMutationData-
base [31] and performs additional in silico prediction of variant conse-
quences using ENSEMBL and UCSC gene annotations [32,33]. RUNES
categorizes each variant according to the American College of Medical
Genetics (ACMG's) recommendations for reporting sequence variation
[34,35] as well as an allele frequency derived from CPGM's Variant
Warehouse database [10]. Brieﬂy, category 1 variants are those previous-
ly described as disease-causing, category 2 variants are those of the type
likely to disrupt protein function and be disease-causing if they are in
a gene associated with disease, and category 3 variants are those of
unknown signiﬁcance that may or may not cause disease.5.4. Capillary sequencing
Primers and PCR conditions are available upon request. PCR
products were puriﬁed using Exo-Sapit (USB Corporation, Cleve-
land, OH) according to the manufacturer's instructions. Both the for-
ward and reverse strands of the puriﬁed PCR product were sequenced
using ﬂuorescent dye-terminator sequencing. Sequencing reactions
were puriﬁed using the BigDye XTerminator Puriﬁcation Kit (Applied
Biosystems, Foster City, CA) according to the manufacturer's instruc-
tions. Results were analyzed on an ABI 3130 analyzer (Applied
Biosystems, Foster City, CA). Sequence results were compared to
published reference sequence (NM_001558.3) using Sequencher
4.5 (Gene Codes Corporation, Ann Arbor, MI).Abbreviations
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